| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer | Chief Corp. Dev. Officer
1 company
Shafique Virani last filed a Form 4 in January 2024, as Chief Business Officer at RXRX. Shafique Virani's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Shafique Virani a strong insider score of 70/100, based on 22 past trades. Over a 12-month horizon, 68.2% of those trades were profitable, with an average 12-month return of +13.2%.
At the last filing, the largest reported position was 136,748 shares of RXRX. The RXRX filings lean toward selling, a net 400,119 shares.
Shafique Virani has 23 Form 4 filings on record from April 2021 to January 2024, all as Chief Business Officer at Recursion Pharmaceuticals (RXRX), 2021–2024.
The 63 reported transactions were 25 open-market sales, 20 option exercises, 9 tax withholdings and 4 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 17 sales worth about $4.2M.
The largest open-market sale was 60,000 shares of RXRX at an average $12.73 on July 18, 2023, about $764K. Twelve months later RXRX was down 39%.
All 10 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from January 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $10.93 | $196,740.00 | -11.6% | -27.6% | -40.3% | |
| Dec 15, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $9.60 | $172,800.00 | -11.6% | +11.1% | -28.4% | |
| Nov 15, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $6.51 | $117,180.00 | -11.4% | +36.4% | -3.8% | |
| Oct 16, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $6.30 | $113,400.00 | -11.4% | +64.3% | +1.8% | |
| Sep 15, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $8.66 | $155,880.00 | -11.4% | +11.2% | -23.3% | |
| Aug 15, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 18,000 | $9.25 | $166,500.00 | -11.4% | -36.6% | -31.7% | |
| Jul 26, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 40,000 | $14.36 | $574,200.00 | -21.7% | -55.5% | -40.9% | |
| Jul 18, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 60,000 | $12.73 | $763,800.00 | -29.4% | -51.9% | -38.7% | |
| Jun 16, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE10b5-1 | 60,000 | $9.54 | $572,400.00 | -29.4% | -3.6% | +3.8% | |
| Jun 2, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Chief Business Officer | Sell10b5-1 | 42,865 | $8.73 | $374,034.45 | -22.9% | +5.7% | +0.6% |